Get started
Author

Maud Rijnders

Observed names: M Rijnders, M. Rijnders, Rijnders, Maud
ORCID: 0000-0002-1552-0813
Observed ORCID: 0000-0002-1552-0813
OpenAlex ID: A5080890610
Systematic Review of Immune Checkpoint Inhibition in Urological Cancers
2017 · Maud Rijnders, Ronald de Wit, et al. · European Urology · 111
Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma
2022 · J. Alberto Nakauma-González, Maud Rijnders, et al. · European Urology · 52
PDF
PD-L1 Antibody Comparison in Urothelial Carcinoma
2018 · Maud Rijnders, Astrid A.M. van der Veldt, et al. · European Urology · 51
PDF
Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes
2020 · Yarne Klaver, Maud Rijnders, et al. · Journal for ImmunoTherapy of Cancer · 43
PDF
Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer
2024 · Maud Rijnders, J. Alberto Nakauma-González, et al. · Nature Communications · 22
PDF
Genome‐wide aneuploidy detected by mFast‐SeqS in circulating cell‐free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer
2022 · Pauline A. J. Mendelaar, Debbie G. J. Robbrecht, et al. · Molecular Oncology · 20
PDF
Whole-genome mapping of APOBEC mutagenesis in metastatic urothelial carcinoma identifies driver hotspot mutations and a novel mutational signature
2024 · J. Alberto Nakauma-González, Maud Rijnders, et al. · Cell Genomics · 17
A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer
2022 · Maud Rijnders, Debbie G. J. Robbrecht, et al. · Cancer Immunology Immunotherapy · 9
PDF
Early response marker during pembrolizumab treatment in metastatic urothelial cancer: Temporal shift in peripheral CD4 T cells expressing chemokine receptors.
2020 · Maud Rijnders, Hayri Emrah Balcioglu, et al. · Journal of Clinical Oncology · 2
Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer
2026 · Youssra Salhi, Stavros Makrodimitris, et al. · Molecular Oncology
Case report: safe reintroduction of pembrolizumab after anti-LGI1 encephalitis
2026 · Maud Rijnders, Anna E. M. Bastiaansen, et al. · Academia oncology.
PDF
Author response for "Longitudinal genome-wide aneuploidy measurements in circulating cell-free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer"
2026 · Youssra Salhi, Stavros Makrodimitris, et al. · Publons reviews and discussion
Genome-wide aneuploidy detected in circulating cell-free DNA of patients with metastatic urothelial cancer as a predictive biomarker of response to pembrolizumab.
2023 · Youssra Salhi, Maud Rijnders, et al. · Journal of Clinical Oncology
PDF
Supplementary figure 6 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells
2023 · Maud Rijnders, Hayri E. Balcioglu, et al.
Supplementary figure 4 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells
2023 · Maud Rijnders, Hayri E. Balcioglu, et al.
PDF
Supplementary figure 1 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells
2023 · Maud Rijnders, Hayri E. Balcioglu, et al.
Data from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells
2023 · Maud Rijnders, Hayri E. Balcioglu, et al.
Supplementary figure legends from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells
2023 · Maud Rijnders, Hayri E. Balcioglu, et al.
Supplementary figure 5 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells
2023 · Maud Rijnders, Hayri E. Balcioglu, et al.
Supplementary figure 8 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells
2023 · Maud Rijnders, Hayri E. Balcioglu, et al.
PDF
Supplementary figure 7 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells
2023 · Maud Rijnders, Hayri E. Balcioglu, et al.
PDF
Supplementary figure 7 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells
2023 · Maud Rijnders, Hayri E. Balcioglu, et al.
Supplementary figure 5 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells
2023 · Maud Rijnders, Hayri E. Balcioglu, et al.
PDF
Supplementary figure 9 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells
2023 · Maud Rijnders, Hayri E. Balcioglu, et al.
Supplementary figure 2 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells
2023 · Maud Rijnders, Hayri E. Balcioglu, et al.
PDF
Works count: 43
Citation count: 327
H-index: 8
I10-index: 7
Year
Topic
Type